PL369311A1 - Zastosowanie wychwytu zwrotnego norepinefryny do leczenia zaburzeń procesów poznawczych - Google Patents
Zastosowanie wychwytu zwrotnego norepinefryny do leczenia zaburzeń procesów poznawczychInfo
- Publication number
- PL369311A1 PL369311A1 PL02369311A PL36931102A PL369311A1 PL 369311 A1 PL369311 A1 PL 369311A1 PL 02369311 A PL02369311 A PL 02369311A PL 36931102 A PL36931102 A PL 36931102A PL 369311 A1 PL369311 A1 PL 369311A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- reuptake inhibitors
- norepinephrine reuptake
- cognitive failure
- cognitive
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33917401P | 2001-12-11 | 2001-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL369311A1 true PL369311A1 (pl) | 2005-04-18 |
Family
ID=23327833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02369311A PL369311A1 (pl) | 2001-12-11 | 2002-11-27 | Zastosowanie wychwytu zwrotnego norepinefryny do leczenia zaburzeń procesów poznawczych |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20050009925A1 (pl) |
| EP (1) | EP1458368B1 (pl) |
| JP (1) | JP2005517647A (pl) |
| KR (1) | KR20040066895A (pl) |
| CN (1) | CN1713900A (pl) |
| AU (1) | AU2002352625A1 (pl) |
| BR (1) | BR0213581A (pl) |
| CA (1) | CA2467802A1 (pl) |
| CO (1) | CO5590907A2 (pl) |
| CZ (1) | CZ2004709A3 (pl) |
| DE (1) | DE60223718T2 (pl) |
| EA (1) | EA200400793A1 (pl) |
| EC (1) | ECSP045145A (pl) |
| ES (1) | ES2295435T3 (pl) |
| HR (1) | HRPK20040528B3 (pl) |
| HU (1) | HUP0402619A3 (pl) |
| IL (1) | IL161989A0 (pl) |
| MX (1) | MXPA04005716A (pl) |
| MY (1) | MY136367A (pl) |
| NO (1) | NO20042904L (pl) |
| NZ (1) | NZ532065A (pl) |
| PL (1) | PL369311A1 (pl) |
| SK (1) | SK2442004A3 (pl) |
| TW (1) | TW200300672A (pl) |
| WO (1) | WO2003049724A1 (pl) |
| ZA (1) | ZA200404274B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0313411A (pt) * | 2002-08-14 | 2005-06-28 | Pharmacia & Upjohn Co Llc | Uso de reboxetina para o tratamento de ondas de calor |
| EP1708717B1 (en) * | 2003-07-28 | 2011-10-05 | Leslie Joe Dunaway | Atomoxetine for treatment of allergic rhinitis and asthma |
| EP1660064A2 (en) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors |
| DE602004014823D1 (de) * | 2003-12-12 | 2008-08-14 | Lilly Co Eli | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen |
| AP2006003771A0 (en) * | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20100317730A1 (en) * | 2009-06-12 | 2010-12-16 | Shaya Elias K | Treatment for menopausal and perimenopausal vasomotor symptons |
| US20110028453A1 (en) * | 2009-07-31 | 2011-02-03 | Wen-Mei Fu | Treating Negative Symptoms of Schizophrenia Associated with Defective Neuregulin 1 |
| US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| JP6313750B2 (ja) | 2013-04-02 | 2018-04-18 | 学校法人同志社 | タウ凝集阻害剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| ATE319453T1 (de) * | 1999-07-01 | 2006-03-15 | Pharmacia & Upjohn Co Llc | Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen |
| NZ517696A (en) * | 1999-10-13 | 2004-12-24 | Pfizer Prod Inc | Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| AU2002243451A1 (en) * | 2001-01-02 | 2002-07-16 | Sention, Inc. | Use of catecholamine reuptake inhibitors to enhance memory |
-
2002
- 2002-11-27 EP EP02789574A patent/EP1458368B1/en not_active Expired - Lifetime
- 2002-11-27 AU AU2002352625A patent/AU2002352625A1/en not_active Abandoned
- 2002-11-27 US US10/496,765 patent/US20050009925A1/en not_active Abandoned
- 2002-11-27 CZ CZ2004709A patent/CZ2004709A3/cs unknown
- 2002-11-27 CA CA002467802A patent/CA2467802A1/en not_active Abandoned
- 2002-11-27 SK SK244-2004A patent/SK2442004A3/sk not_active Application Discontinuation
- 2002-11-27 DE DE60223718T patent/DE60223718T2/de not_active Expired - Fee Related
- 2002-11-27 EA EA200400793A patent/EA200400793A1/ru unknown
- 2002-11-27 HU HU0402619A patent/HUP0402619A3/hu unknown
- 2002-11-27 IL IL16198902A patent/IL161989A0/xx unknown
- 2002-11-27 MX MXPA04005716A patent/MXPA04005716A/es not_active Application Discontinuation
- 2002-11-27 NZ NZ532065A patent/NZ532065A/en unknown
- 2002-11-27 JP JP2003550773A patent/JP2005517647A/ja active Pending
- 2002-11-27 WO PCT/US2002/036132 patent/WO2003049724A1/en not_active Ceased
- 2002-11-27 BR BR0213581-7A patent/BR0213581A/pt not_active IP Right Cessation
- 2002-11-27 KR KR10-2004-7009039A patent/KR20040066895A/ko not_active Withdrawn
- 2002-11-27 CN CNA028247264A patent/CN1713900A/zh active Pending
- 2002-11-27 PL PL02369311A patent/PL369311A1/pl unknown
- 2002-11-27 ES ES02789574T patent/ES2295435T3/es not_active Expired - Lifetime
- 2002-11-27 HR HR20040528A patent/HRPK20040528B3/xx not_active IP Right Cessation
- 2002-12-05 MY MYPI20024591A patent/MY136367A/en unknown
- 2002-12-05 TW TW091135296A patent/TW200300672A/zh unknown
-
2004
- 2004-05-31 ZA ZA200404274A patent/ZA200404274B/en unknown
- 2004-06-09 EC EC2004005145A patent/ECSP045145A/es unknown
- 2004-06-09 CO CO04054292A patent/CO5590907A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042904A patent/NO20042904L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200400793A1 (ru) | 2004-10-28 |
| NO20042904L (no) | 2004-09-07 |
| HRP20040528A2 (en) | 2004-10-31 |
| DE60223718T2 (de) | 2008-10-30 |
| EP1458368B1 (en) | 2007-11-21 |
| ZA200404274B (en) | 2005-09-13 |
| CO5590907A2 (es) | 2005-12-30 |
| JP2005517647A (ja) | 2005-06-16 |
| WO2003049724A1 (en) | 2003-06-19 |
| ECSP045145A (es) | 2004-07-23 |
| KR20040066895A (ko) | 2004-07-27 |
| EP1458368A1 (en) | 2004-09-22 |
| CA2467802A1 (en) | 2003-06-19 |
| US20050009925A1 (en) | 2005-01-13 |
| IL161989A0 (en) | 2005-11-20 |
| SK2442004A3 (en) | 2004-12-01 |
| HRPK20040528B3 (en) | 2006-03-31 |
| NZ532065A (en) | 2007-03-30 |
| DE60223718D1 (de) | 2008-01-03 |
| CZ2004709A3 (cs) | 2004-10-13 |
| CN1713900A (zh) | 2005-12-28 |
| HUP0402619A3 (en) | 2008-04-28 |
| MXPA04005716A (es) | 2004-12-06 |
| HUP0402619A2 (hu) | 2005-03-29 |
| AU2002352625A1 (en) | 2003-06-23 |
| ES2295435T3 (es) | 2008-04-16 |
| TW200300672A (en) | 2003-06-16 |
| MY136367A (en) | 2008-09-30 |
| BR0213581A (pt) | 2004-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL373568A1 (pl) | Zastosowanie inhibitorów kinazy I kappa B w leczeniu bólu | |
| NO20035609L (no) | Fremgangsmate for kontinuerlig naftabehandling | |
| IL159347A0 (en) | Arylamines for the treatment of conditions associated with gsk-3 | |
| IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
| IL160884A0 (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
| NO20014047L (no) | Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser | |
| WO2004047830A3 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen | |
| IL209319A0 (en) | Substituted tetracycline compounds for the treatment of malaria | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| EP1448205A4 (en) | COMBINATIONS FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISEASES | |
| IL161989A0 (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
| IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
| PL377552A1 (pl) | Leczenie zespołu nadpobudliwości psychoruchowej z deficytem uwagi | |
| IL162308A0 (en) | Aminoindane derivatives as serotonin and norepinephrine uptakeinhibitors | |
| EP1461030A4 (en) | AMINOALKYL-BENZOFURAN-5-OL COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| IL161748A0 (en) | New use for the treatment of gastroesophageal reflux | |
| PT1530462E (pt) | Compostos 1-fenil-2-dimetilaminometilciclo-hexano utilizados na terapia dos sintomas depressivos, dor e incontinência | |
| HK1069540A (en) | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure | |
| GB2410744B (en) | Kinase inhibitors for the treatment of disease | |
| AU2003227521A1 (en) | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain | |
| IL162492A0 (en) | Use of alkylphosphocholines for the preventative treatment of protozoandiseases | |
| GB2409655B (en) | Treatment of fluids | |
| AU2003290363A8 (en) | Therapeutic use of selective noradrenaline reuptake inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |